Everest Organics Ltd

₹ 265 -3.60%

11 Sep - close price

About

Everest Organics Ltd (EOL) makes active pharmaceutical ingredients (APIs), the main medicinal ingredients in finished medicines,
and chemical intermediates used to make APIs. Its factory is at Aroor, Sangareddy, Telangana.^[1]

Key Points

Product Profile:
a) APIs:^[1]
Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia
and Gout, Anti Thrombotic, Anti Fungal,
Anti Viral, Anti Emetics, Anti Diabetic,
Insomnia, Skeletal muscle relaxant,
Overactive Bladder, Rhino-Conjunctivitis,
etc.
b) Intermediates:^[2]
Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate, Rivaroxaban, Itraconazole, Omeprazole, Pantoprazole, Rabeprazole, Esomeprazole, Pemetrexed, Pregabalin, Hydroxy, Chloro compound,
Sulphide, Pyrazine, Gancyclovir, Apixaban, Aprepitant, Bilastine, etc.
c) By Products:^[2]
Ammonium Sulphate, Sodium Nitrite, Di
Sodium Orthophosphate, Di Ammonium
Phosphate

Website BSE

Market Cap ₹ 264 Cr.
Current Price ₹ 265
High / Low ₹ 536 / 197
Stock P/E 50.3
Book Value ₹ 77.7
Dividend Yield 0.00 %
ROCE 12.0 %
ROE 7.63 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

Stock is trading at 3.41 times its book value
The company has delivered a poor sales growth of 1.56% over past five years.
Company has a low return on equity of 2.49% over last 3 years.
Company has high debtors of 216 days.
Promoter holding has decreased over last 3 years: -14.6%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	42.67	49.45	52.51	52.62	32.45	44.05	42.05	40.93	53.81	51.00	42.59	48.75	48.43
	40.15	46.74	49.71	49.67	36.11	40.62	38.03	37.49	49.37	45.87	39.05	42.05	44.10
Operating Profit	2.52	2.71	2.80	2.95	-3.66	3.43	4.02	3.44	4.44	5.13	3.54	6.70	4.33
OPM %	5.91%	5.48%	5.33%	5.61%	-11.28%	7.79%	9.56%	8.40%	8.25%	10.06%	8.31%	13.74%	8.94%
	0.22	0.24	0.13	0.30	0.33	0.14	0.00	0.22	0.55	0.29	0.25	0.16	0.42
Interest	1.29	1.49	1.45	1.24	1.29	1.35	1.40	1.15	1.31	1.23	1.23	2.76	1.63
Depreciation	1.29	1.32	1.33	1.85	1.47	1.47	1.47	1.56	1.52	1.52	1.52	1.93	1.59
Profit before tax	0.16	0.14	0.15	0.16	-6.09	0.75	1.15	0.95	2.16	2.67	1.04	2.17	1.53
Tax %	75.00%	78.57%	93.33%	62.50%	0.00%	1.33%	0.87%	-206.32%	35.19%	56.93%	65.38%	-21.20%	26.80%
	0.04	0.03	0.02	0.06	-6.09	0.74	1.14	2.91	1.41	1.16	0.36	2.63	1.11
EPS in Rs	0.05	0.04	0.02	0.08	-7.61	0.92	1.42	3.00	1.45	1.19	0.37	2.71	1.14
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	106	99	107	112	156	167	182	200	183	197	159	196	191
	98	94	101	105	138	148	159	194	182	186	152	176	171
Operating Profit	8	6	6	7	18	19	23	6	1	11	7	20	20
OPM %	7%	6%	6%	6%	11%	11%	13%	3.2%	0.5%	6%	4.5%	10%	10%
	-0	-0	1	1	1	1	1	2	7	1	1	1	1
Interest	3	3	3	3	3	3	3	3	3	5	5	7	7
Depreciation	3	3	2	3	3	3	3	4	4	6	6	6	7
Profit before tax	2	0	2	2	12	14	17	2	0	1	-3	8	7
Tax %	20%	18%	24%	28%	39%	23%	21%	34%	311%	77%	-60%	31%
	2	0	1	2	8	11	14	1	-0	0	-1	6	5
EPS in Rs		0.54	1.69	2.14	9.39	13.62	17.15	1.42	-0.22	0.18	-1.33	5.72	5.41
Dividend Payout %	0%	0%	0%	0%	11%	7%	9%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	7%
5 Years:	2%
3 Years:	2%
TTM:	5%

Compounded Profit Growth
10 Years:	21%
5 Years:	-17%
3 Years:	315%
TTM:	-15%

Stock Price CAGR
10 Years:	19%
5 Years:	-4%
3 Years:	30%
1 Year:	-36%

Return on Equity
10 Years:	10%
5 Years:	2%
3 Years:	2%
Last Year:	8%

Balance Sheet

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	9	3	8	8	8	8	8	8	8	8	10	10
Reserves	-3	3	8	11	18	26	39	39	38	38	60	66
	24	28	19	22	21	18	23	39	51	58	48	50
	37	42	51	54	60	68	66	92	105	123	107	114
Total Liabilities	67	76	86	94	107	120	135	178	202	227	224	240
	24	27	33	34	38	39	44	49	54	52	50	48
CWIP	0	1	1	1	0	1	0	8	12	21	23	21
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	42	47	52	60	68	80	92	121	136	153	152	171
Total Assets	67	76	86	94	107	120	135	178	202	227	224	240

Cash Flows

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	7	10	5	9	10	14	14	18	16	-5	4
	-3	-7	-8	-4	-5	-6	-12	-17	-16	-13	-5	-2
	-2	-0	-2	-1	-3	-3	-2	2	-3	-3	16	-8
Net Cash Flow	-0	0	0	-0	1	0	-0	-1	0	0	6	-6
Free Cash Flow	1	0	2	1	2	3	7	-3	5	3	-11	2
CFO/OP	52%	119%	162%	64%	50%	51%	59%	214%	1,981%	149%	-76%	21%

Ratios

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	100	117	105	124	95	97	102	125	152	185	202	216
Inventory Days	44	55	73	72	71	102	110	110	139	128	166	133
Days Payable	184	235	260	251	190	211	183	212	282	324	351	264
Cash Conversion Cycle	-40	-63	-83	-55	-24	-12	29	24	9	-11	17	85
Working Capital Days	-30	-38	-50	-34	-15	7	21	9	-12	-20	3	27
ROCE %	19%	11%	13%	13%	35%	35%	34%	6%	4%	6%	2%	12%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Capacity Utilization - Benzimidazole
%

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xx.xx	xx.xx	xx.xx
xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx		xx.xx	xx.xx	xx.xx
					xx	xx	xx	xx		xx
					xx	xx	xx	xx		xx

Please log in to see hidden values.

Capacity Utilization - Esomeprazole
%

Production Volume - Benzimidazole
MT

Production Volume - Esomeprazole Magnesium
MT

Production Volume - Omeprazole Powder
MT

Capacity Utilization - Omeprazole
%

Number of Clients
count

Number of Countries Served
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.15%	74.15%	74.15%	74.15%	74.15%	74.15%	61.09%	60.99%	59.64%	59.61%	59.58%	59.60%
	0.03%	0.03%	0.03%	0.03%	0.05%	0.05%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
	25.82%	25.82%	25.83%	25.83%	25.81%	25.80%	38.90%	38.99%	40.35%	40.36%	40.40%	40.38%
No. of Shareholders	10,494	10,242	10,023	9,792	9,996	9,326	8,756	8,281	8,079	7,804	7,880	7,827

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	72.82%	73.18%	73.27%	73.79%	74.15%	74.15%	74.15%	74.15%	61.09%	59.58%	59.60%
	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.02%	0.02%	0.02%
	27.15%	26.79%	26.71%	26.19%	25.82%	25.82%	25.83%	25.83%	38.90%	40.40%	40.38%
No. of Shareholders	7,878	7,567	7,431	7,110	8,122	11,154	10,834	10,023	8,756	7,880	7,827

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Everest Organics Ltd

Everest Organics Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls